Torrance, CA (February 7, 2018): Calling the day a “major milestone,” Los Angeles County Supervisor Mark Ridley-Thomas joined officials of LA BioMed for the topping off ceremony of their 78,000 square foot research building and incubator that is an integral component of LA County’s 1st Biotech Hub, emerging in the heart of LA BioMed’s 11.5-acre research park adjacent to Harbor-UCLA Medical Center in Torrance.
July 7, 2017
The U.S. Food and Drug Administration today approved Endari (L-glutamine oral powder) for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder.
Offers Additional Resources to Help its Startups Succeed
LOS ANGELES – (June 16, 2017) – LA BioMed is launching a Commercialization Accelerator Program™ (CAP), designed and implemented by Larta Institute, that will offer LA BioMed’s early stage bioscience companies additional resources to strengthen and speed their innovations to the marketplace, Keith B. Hoffman, PhD, LA BioMed vice president of business development and technology transfer, and Rohit Shukla, Larta Institute CEO, announced today.
Dr. Edwards Receives the Rhoda Benham Award from Medical Mycology Society
“Congratulations to Dr. Edwards for this important recognition of his many accomplishments and contributions to this field of scientific study,” said David I. Meyer, PhD, LA BioMed president and CEO. “For more than three decades, Dr.
Proceeds to Help Fund Institute’s Groundbreaking Research and New Facilities
LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers. Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.
TORRANCE, Calif., May 24, 2017 /PRNewswire/ -- Emmaus Life Sciences Inc. announced today that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of EndariTM for the treatment of sickle cell disease (SCD) is favorable. The FDA has set a PDUFA target action date for July 7, 2017.
LOS ANGELES – (May 18, 2017) – LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers.
Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.
LA BioMed Researcher Honored for Outstanding Work in Liver Disease
The Research Society on Alcoholism (RSA), an organization of researchers who specialize in the study of alcoholism, will honor Samuel W. French, MD, a lead researcher at LA BioMed, with its prestigious 2017 Lifetime Achievement Award for his outstanding work in the field of alcohol research at the organization’s annual scientific meeting in Denver on June 28.